Andrew Guggenhime

PCVX CFO Guggenhime sells 10,000 shares ($530.0K) under scheduled 10b5-1 plan; retains 104.4K shares plus 236,827 stock options

Andrew Guggenhime, PRESIDENT AND CFO, sold 10,000 shares of Vaxcyte (PCVX) at $53.00 on 2026-06-18 as part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-04—a scheduled, non-discretionary transaction. This sale reduces his non-derivative holdings from 114.4K shares to 104.4K shares (-8.7%), but he retains substantial equity exposure through 236,827 stock options. His prior sales at PCVX show consistent weakness in subsequent performance: five prior sells between January–February 2025 recorded 30-day declines ranging from -4.2% to -12.0% and 90-day declines from -61.7% to -65.4%. The current stock price of $51.44 is -20.9% from its 52-week high of $65.00, and the company remains unprofitable with net income of -$320.6M. The scheduled nature of this trade removes discretionary timing as a signal, but the historical pattern of negative returns following his prior PCVX sales underscores elevated volatility and fundamental weakness in the stock's recent trajectory.

CFO Andrew Guggenhime sold 8,000 shares at $83.85 avg, reducing stake 6.8%; stock down 29.3% from 52-week high.

Andrew Guggenhime, President and CFO, executed 2 separate sales totaling 8,000 shares for $670,822.74 on 2025-02-18, reducing his holdings from 117,491 to 109,491 shares. The sales occurred at a blended average price of $83.85, while the stock currently trades at $83.36, near recent lows and 29.3% below its 52-week high of $117.93. Vaxcyte remains unprofitable with a net loss of $103,124,000.00 over its most recent full fiscal year. While Guggenhime's cross-ticker track record shows a 90-day well-timed selling rate of 61.54%, his prior sales at PCVX specifically have not yet demonstrated measurable outcomes at the 90-day mark, and his three most recent PCVX sales on 2025-01-21 lack measurable returns, limiting forward-looking inference from this particular insider's historical accuracy at this ticker.

PCVX CFO sells 8,000 shares for $692,100.56; fifth sale in 34 days as stock falls -22.9% in 90 days.

Andrew Guggenhime (President and CFO) executed 3 separate sales totaling 8,000 shares for $692,100.56 on 2025-01-21, reducing holdings from 117,491 to 109,491 shares. This is the fifth discrete transaction in January and December 2024—prior same-ticker sales on 2024-12-18 and 2024-11-18 followed a similar pattern. The stock has declined -22.9% over 90 days and is trading -26.5% below its 52-week high of $117.93. While his cross-ticker track record shows a 90-day well-timed rate of 38.46% across 20 prior sales, his PCVX-specific prior trades show adverse outcomes: all four measurable prior sales at this ticker posted negative 30-day returns (ranging from -0.8% to -5.5%). The company is unprofitable with a net loss of $103,124,000.00 in the most recent full fiscal year. The repeated execution of multiple daily sales over consecutive weeks, combined with the persistent post-sale negative returns at this ticker, warrants investor attention to whether near-term business or valuation developments are driving the liquidation activity.

PCVX President/CFO Guggenhime sells 8,000 shares for $710,248.57 on 2024-12-18; stock down 26.9% from 52-week high.

Guggenhime executed 4 separate sales totaling 8,000 shares for $710,248.57 at blended average price $88.78, reducing his holdings by 6.8% from 117.5K to 109.5K shares. The timing is notable relative to the stock's 52-week trajectory: he sold at $86.21–$90.24 while the stock currently trades at $86.21, down 26.9% from its $117.93 high and 25.2% lower over the prior 90 days. His cross-ticker track record shows a 90-day well-timed rate of 20.00% across 20 prior sells, but at PCVX specifically, none of his 5 prior measurable trades have generated positive 90-day returns—the most recent sales on 2024-10-18 saw 30-day declines of -24.7% and -25.3%. The company reported a -$103.1M net loss over its most recent full fiscal year, providing fundamental context for the stock's weakness. This sale occurs as the stock approaches its recent lows, though whether this represents prescient positioning or reactive selling is not determinable from price action alone.

PCVX CFO Andrew Guggenheim sold 8,000 shares for $686.5K at blended $85.81 on 2024-11-18

Andrew Guggenheim, President and CFO, executed 3 separate sales totaling 8,000 shares for $686,517.55 at an average price of $85.81, reducing his position from 117.5K to 109.5K shares (a 6.8% reduction). The company is unprofitable with a full-year net income of $-103.1M, and the stock has declined 24.6% over the past 30 days and 26.2% from its 52-week high of $117.93, trading at $87.08 currently. His prior trades at PCVX show a pattern of selling into declining prices: recent sales on 2024-10-18 resulted in 30-day declines of 24.7% and 25.3%, suggesting sales occurred near local peaks. While his cross-ticker track record shows 0% 90-day well-timed sell outcomes across 20 prior trades, his same-ticker pattern suggests these transactions may reflect the ongoing stock weakness rather than forward-looking confidence in the company's trajectory.

PCVX CFO sold 42,000 shares at blended avg $115.39, reducing stake 31.7%; stock now -4.5% from 52-week high.

Andrew Guggenhime, President and CFO, executed 2 separate sales totaling 42,000 shares for $4,846,508.21 on 2024-10-18 at prices near the 52-week high of $117.93. This represents a -31.7% reduction in his holdings from 132,383 to 90,383 shares. The sales occurred during a period of strong momentum (90-day return of +32.3%), but his cross-ticker track record shows limited predictive value: 19 prior sells averaged a 90-day return of +24.3% (poorly timed, since the stock rose after he sold) with a 0.00% well-timed rate. At PCVX specifically, his 5 prior trades show mixed outcomes with no measurable 90-day results yet. The company remains unprofitable with a net income of $-128,703,000.00 over the most recent fiscal year, which provides broader context for the magnitude of the reduction in executive equity exposure.

PCVX CFO/President Guggenhime sells 8,000 shares for $927,550.51 at $115.94 avg; stock now at 52-week high.

Andrew Guggenhime, President and CFO of Vaxcyte, executed 3 separate sales totaling 8,000 shares for $927,550.51 on 2024-09-18, reducing his holdings from 98,383 to 90,383 shares (a -8.1% reduction). The blended average sale price of $115.94 is within the narrow band of the 3 transaction prices ($115.60–$117.53), and the current price of $117.12 sits at the 52-week high ($45.35–$117.12), indicating the stock has rallied 48.2% in the 30 days and 56.3% in the 90 days following a recent pattern of insider selling at this ticker. His prior 5 sales at PCVX between July and August showed mixed post-sale returns, with two trades posting substantial 30-day gains (+47.3%, +48.9%) and three showing declines (-1.5%, -5.1%, -4.2%), suggesting volatility in the stock's behavior post-sale. Context: the company reported net income of $-128,703,000.00 on a $13.1B market cap, reflecting ongoing unprofitability, which frames this sale against a backdrop of fundamental weakness despite the sharp recent price appreciation.

CFO Guggenhime sells 8,000 PCVX shares for $628,650.32; holds 96,720 post-trade amid -$128.7M annual loss.

President and CFO Andrew Guggenhime executed 2 separate sales totaling 8,000 shares for $628,650.32 on 2024-08-19, reducing holdings by 7.6% to 96,720 shares. The company reported a full-year net income of -$128,703,000.00 and operates with an $8.8B market cap while unprofitable. His prior sales at PCVX over the preceding two months (five trades on 2024-07-18 and 2024-06-18) showed mixed near-term outcomes, with 30-day returns ranging from -5.1% to +10.7%, and his cross-ticker track record across 14 prior sells shows an average 90-day return of +5.8% with 0% well-timed rate. The sale was executed near the 52-week high (current price $79.01 is -7.2% from $85.16 high), though this appears consistent with routine post-acquisition or portfolio rebalancing activity rather than a discontinuous signal of operational deterioration.

PCVX CFO Guggenheim sells 8,000 shares ($649.3K) at $81.17 avg; stock now $84.05, near 52-week high. Company unprofitable.

CFO Andrew Guggenheim executed 4 separate sales totaling 8,000 shares for $649,325.13 at prices ranging from $80.12 to $83.14 on 2024-07-18, reducing his holdings by 7.6% to 96,720 shares. The sale occurred at a blended average price of $81.17, roughly 3.4% below the current price of $84.05 and just 0.1% below the stock's 52-week high of $84.17, suggesting the sales were executed near recent peak valuation. Vaxcyte posted a net loss of $95,020,000 over its most recent full fiscal year, yet the stock has appreciated 38.1% over the past 90 days and 12.2% over the past 30 days; the CFO's recent prior sales at this ticker (June and May 2024) were followed by positive 30-day returns of +9.6%, +10.7%, -2.9%, and -4.2%, with the one measurable 90-day outcome (March 2024 sale) showing a modest +4.7% return rather than downside. This filing warrants examination of the company's current operational trajectory and whether near-peak-price selling by senior management signals a shift in executive perspective on valuation.

CFO Andrew Guggenhime sold 8,000 shares at blended avg $71.92; prior same-ticker sells have underperformed 90d reversal pattern.

Andrew Guggenhime, President and CFO, executed two separate sales on 2024-06-18 totaling 8,000 shares for $575,374.73 (7,652 shares at $71.89 and 348 shares at $72.56), reducing holdings from 104,720 to 96,720 shares. At the blended average price of $71.92, the transaction occurred just below the current price of $72.76. Examining his prior trades at PCVX reveals a consistent pattern: five earlier sales have returned negative 30-day outcomes (-2.9% to -10.4%) and, critically, zero of three measurable 90-day post-sale windows showed the negative returns that would indicate well-timed insider exits (instead showing +2.5% to +5.7% reversals). The company's unprofitable fiscal year (net income of $-95,020,000.00) adds fundamental context to insider dispositions. While the sales represent a 7.6% reduction in his holdings, the historical timing pattern at this ticker provides no evidence that his prior sales anticipated material declines.